Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 1
1996 1
1998 2
2001 1
2004 1
2007 1
2008 2
2009 1
2011 3
2012 2
2013 2
2015 3
2016 3
2017 3
2018 1
2019 6
2020 5
2021 4
2022 4
2023 6
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

51 results

Results by year

Filters applied: . Clear all
Page 1
Trastuzumab deruxtecan in previously treated HER2-positive metastatic or unresectable breast cancer: Real-life data from the temporary use authorization program in France.
Petit T, Hajjaji N, Antoine EC, Benderra MA, Gozy M, Foa C, Mouysset JL, Grenier J, Mousseau M, Mailliez A, Saghatchian M, Lachaier E, Desmoulins I, Hennequin A, Maes P, Loirat D, Ricci F, Diéras V, Berton D, Tiong FL, Teixeira L, Dohollou N, Lévy C, Bachelot T, Pierga JY. Petit T, et al. Among authors: dohollou n. Cancer Med. 2024 May;13(9):e7168. doi: 10.1002/cam4.7168. Cancer Med. 2024. PMID: 38733172
Spatial profiling of ovarian carcinoma and tumor microenvironment evolution under neoadjuvant chemotherapy.
Yaniz-Galende E, Zeng Q, Grau-Bejar JF, Klein C, Blanc-Durand F, Le Formal A, Pujade-Lauraine E, Chardin L, Edmond E, Marty V, Ray-Coquard I, Joly F, Ferron G, Pautier P, Berton-Rigaud D, Lortholary A, Dohollou N, Desauw C, Fabbro M, Malaurie E, Bonichon-Lamichhane N, Bello Roufai D, Gantzer J, Rouleau E, Genestie C, Leary A. Yaniz-Galende E, et al. Among authors: dohollou n. Clin Cancer Res. 2024 Apr 26. doi: 10.1158/1078-0432.CCR-23-3836. Online ahead of print. Clin Cancer Res. 2024. PMID: 38669064
Recommandations francophones pour la pratique clinique concernant la prise en charge des cancers du sein de Saint-Paul-de-Vence 2022-2023.
Gligorov J, Benderra MA, Barthere X, de Forceville L, Antoine EC, Cottu PH, Delaloge S, Pierga JY, Belkacemi Y, Houvenaegel G, Pujol P, Rivera S, Spielmann M, Penault-Llorca F, Namer M; et l'ensemble des experts des votes des RPC Saint-Paul 2022-2023. Gligorov J, et al. Bull Cancer. 2023 Nov;110(10S):10S1-10S43. doi: 10.1016/S0007-4551(23)00473-3. Bull Cancer. 2023. PMID: 38061827
Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer.
Leman R, Muller E, Legros A, Goardon N, Chentli I, Atkinson A, Tranchant A, Castera L, Krieger S, Ricou A, Boulouard F, Joly F, Boucly R, Dumont A, Basset N, Coulet F, Chevalier LM, Rouleau E, Leitner K, González-Martin A, Gargiulo P, Lück HJ, Genestie C; PAOLA-1 investigators; Ray-Coquard I, Pujade-Lauraine E, Vaur D. Leman R, et al. Clin Cancer Res. 2023 Nov 1;29(21):4419-4429. doi: 10.1158/1078-0432.CCR-23-0898. Clin Cancer Res. 2023. PMID: 37756555 Free PMC article.
Atezolizumab and paclitaxel as first line therapy in advanced triple-negative breast cancer patients included in the French early access program.
de Moura A, Vuagnat P, Renouf B, Pierga JY, Loirat D, Vaflard P, Lafayolle de la Bruyère C, Chaumard-Billotey N, Hajjaji N, Ladoire S, Dabakuyo S, Patsouris A, Frenel JS, Nicolai V, Alexandre M, Dohollou N, Grenier J, Bourien H, Bidard FC. de Moura A, et al. Among authors: dohollou n. Sci Rep. 2023 Aug 18;13(1):13427. doi: 10.1038/s41598-023-40569-9. Sci Rep. 2023. PMID: 37596388 Free PMC article.
Corrigendum to "A RAD51 functional assay as a candidate test for homologous recombination deficiency in ovarian cancer".
Blanc-Durand F, Yaniz-Galende E, Llop-Guevara A, Genestie C, Serra V, Herencia-Ropero A, Klein C, Berton D, Lortholary A, Dohollou N, Desauw C, Fabbro M, Malaurie E, Bonichon-Lamaichhane N, Dubot C, Kurtz JE, de Rauglaudre G, Raban N, Chevalier-Place A, Ferron G, Kaminsky MC, Kramer C, Rouleau E, Leary A. Blanc-Durand F, et al. Among authors: dohollou n. Gynecol Oncol. 2023 Aug;175:194. doi: 10.1016/j.ygyno.2023.05.058. Epub 2023 Jun 2. Gynecol Oncol. 2023. PMID: 37271667 No abstract available.
A RAD51 functional assay as a candidate test for homologous recombination deficiency in ovarian cancer.
Blanc-Durand F, Yaniz-Galende E, Llop-Guevara A, Genestie C, Serra V, Herencia-Ropero A, Klein C, Berton D, Lortholary A, Dohollou N, Desauw C, Fabbro M, Malaurie E, Bonichon-Lamaichhane N, Dubot C, Kurtz JE, de Rauglaudre G, Raban N, Chevalier-Place A, Ferron G, Kaminsky MC, Kramer C, Rouleau E, Leary A. Blanc-Durand F, et al. Among authors: dohollou n. Gynecol Oncol. 2023 Apr;171:106-113. doi: 10.1016/j.ygyno.2023.01.026. Epub 2023 Mar 1. Gynecol Oncol. 2023. PMID: 36868112
Neoadjuvant chemotherapy with or without nintedanib for advanced epithelial ovarian cancer: Lessons from the GINECO double-blind randomized phase II CHIVA trial.
Ferron G, De Rauglaudre G, Becourt S, Delanoy N, Joly F, Lortholary A, You B, Bouchaert P, Malaurie E, Gouy S, Kaminsky MC, Meunier J, Alexandre J, Berton D, Dohollou N, Dubot C, Floquet A, Favier L, Venat-Bouvet L, Fabbro M, Louvet C, Lotz JP, Abadie-Lacourtoisie S, Desauw C, Del Piano F, Leheurteur M, Bonichon-Lamichhane N, Rastkhah M, Follana P, Gantzer J, Ray-Coquard I, Pujade-Lauraine E. Ferron G, et al. Among authors: dohollou n. Gynecol Oncol. 2023 Mar;170:186-194. doi: 10.1016/j.ygyno.2023.01.008. Epub 2023 Jan 25. Gynecol Oncol. 2023. PMID: 36706645 Clinical Trial.
Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial.
Bidard FC, Hardy-Bessard AC, Dalenc F, Bachelot T, Pierga JY, de la Motte Rouge T, Sabatier R, Dubot C, Frenel JS, Ferrero JM, Ladoire S, Levy C, Mouret-Reynier MA, Lortholary A, Grenier J, Chakiba C, Stefani L, Plaza JE, Clatot F, Teixeira L, D'Hondt V, Vegas H, Derbel O, Garnier-Tixidre C, Canon JL, Pistilli B, André F, Arnould L, Pradines A, Bièche I, Callens C, Lemonnier J, Berger F, Delaloge S; PADA-1 investigators. Bidard FC, et al. Lancet Oncol. 2022 Nov;23(11):1367-1377. doi: 10.1016/S1470-2045(22)00555-1. Epub 2022 Sep 29. Lancet Oncol. 2022. PMID: 36183733 Clinical Trial.
Maintenance olaparib plus bevacizumab in patients with newly diagnosed advanced high-grade ovarian cancer: Main analysis of second progression-free survival in the phase III PAOLA-1/ENGOT-ov25 trial.
González-Martín A, Desauw C, Heitz F, Cropet C, Gargiulo P, Berger R, Ochi H, Vergote I, Colombo N, Mirza MR, Tazi Y, Canzler U, Zamagni C, Guerra-Alia EM, Levaché CB, Marmé F, Bazan F, de Gregorio N, Dohollou N, Fasching PA, Scambia G, Rubio-Pérez MJ, Milenkova T, Costan C, Pautier P, Ray-Coquard I; PAOLA1/ENGOT-ov25 investigators. González-Martín A, et al. Among authors: dohollou n. Eur J Cancer. 2022 Oct;174:221-231. doi: 10.1016/j.ejca.2022.07.022. Epub 2022 Sep 5. Eur J Cancer. 2022. PMID: 36067615 Free article. Clinical Trial.
51 results